==== Reference: Usmani SS, Bedi G, Samuel JS, Singh S, Kalra S, Kumar P, et al. (2017) THPdb: Database of FDA-approved peptide and protein therapeutics. PLoS ONE 12(7) e0181748.====

Detailed description page of THPdb


Details of Th1228 which contains 1 entries.


Entry 1
(1) Primary information
ID1839
ThPP IDTh1228
Therapeutic Peptide/Protein NameFactor IX Complex (Human)
SequenceNA view full sequnce in fasta
Functional ClassificationIb
Molecular WeightNA
Chemical FormulaNA
Isoelectric PointNA
HydrophobicityNA
Melting Point (℃)NA
Half Life11-28 hr
DescriptionFactor IX Complex is a sterile, lyophilized concentrate composed of a number of Vitamin K-dependent clotting factors found in functioning human plasma. Also known as prothrombin complex concentrate, products containing this complex often include Factor IX (antihemophilic factor B), Factor II (prothrombin), Factor X (Stuart-Prower Factor), and low levels of Factor VII (proconvertin) derived from human plasma. Many commercially available products also contain low levels of other antithrombotic proteins. For example, Kcentra (FDA) also contains the antithrombotic proteins C and S, while Bebulin VH (FDA) contains heparin. Coagulation factors are purified from pooled human plasma and subsequently sterilized and treated. Although Factor IX Complex products contain many different coagulation components, Factor IX is the lead component for potency and efficacy, particularly when used for the treatment of bleeding associated with Hemophilia B (Factor IX deficiency). As the product Kcentra, Factor IX Complex is also indicated for the urgent reversal of acquired coagulation factor deficiency induced by Vitamin K antagonist (VKA, e.g., warfarin) therapy in adult patients experiencing acute major bleeding or requiring rapid reversal of therapy.
Indication/DiseaseFactor IX Complex is indicated for the prevention and control of hemorrhagic episodes in hemophilia B patients. It is also indicated for the urgent reversal of acquired coagulation factor deficiency induced by Vitamin K antagonist (VKA, e.g., warfarin) therapy in adult patients with acute major bleeding or who require rapid reversal of therapy.
PharmacodynamicsNA
Mechanism of ActionFactor IX is a vitamin K-dependent coagulation factor sythesized in the liver; purified FActor IX from human plasma temporarily replace missing clotting factor IX to correct and/or prevent bleeding.
ToxicityNA
MetabolismNA
AbsorptionNA
Volume of DistributionNA
ClearanceNA
CategoriesAntihemophilic agent
Patents NumberNA
Date of IssueNA
Date of ExpiryNA
Drug InteractionNA
TargetNA
Information of corresponding available drug in the market
Brand NameAlphaNine SD or Mononine
Company
Brand DiscriptionIt is a man-made protein that is similar to a natural protein in the body that helps the blood to clot.
Prescribed fors used to treat or prevent bleeding in people with hemophilia B
Chemical NameNA
FormulationNA
Physcial AppearancePowder and solvent for solution for injection
Route of AdministrationIntravenous
Recommended DosageAlphaNine SD, Mononine: 1 unit/kg x body wt (kg) x desired increase (% of normal) = Number of factor IX units required
Contraindication
Side Effects
Useful Link http://www.rxlist.com/profilnine-drug.htm , https://www.drugs.com/monograph/factor-ix-human-factor-ix-complex-human.html ,https://en.wikipedia.org/wiki/Prothrombin_complex_concentrate, http://reference.medscape.com/drug/alphanine-mononine-factor-ix-342157#0
PubMed ID26685667, 27546767, 27488143
3-D StructureN.A.